Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC206 in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Phase 2Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ONC206 in pheochromocytoma, Paraganglioma (PGL), sponsored by Jazz Pharmaceuticals plc. Started Jan 2026; status: recruiting.
02
Drugs
ONC206
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT07282587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282587.